ERBB2 and neoplasm: To address ICG’s limited tissue penetration from short-wavelength emission, π-extended ICG derivatives conjugated with Human Epidermal Growth Factor Receptor 2 (HER2+)/Epidermal Growth Factor Receptor (EGFR+) antibodies enable deep-tumor NIR imaging in HER2+/EGFR+ subtypes [74].